Fig.1 Body weight (A) and body weight change (B) of IMQ induced Psoriasis model in hIL17A/hIL17F mice. (n=6). 

Test article 1 and test article 2 are from a collaborator.

Fig.2 IMQ induced Psoriasis model in hIL17A/hIL17F mice. (A) ear thickness (B) skin thickness (C) clinical score (n=6). 

Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05, **P < 0.01, ***P < 0.001.

Fig.3 IMQ induced Psoriasis model in hIL17A/hIL17F mice. 

At the study endpoint, back skin samples were harvested and stained with H&E. Representative H&E staining images of the back skin from mice and histological changes were quantified using Baker system.  Results indicated that Bimekizumab significantly reduced skin lesions in IMQ induced Psoriasis model in hIL17A/hIL17F mice (n=6). 

Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, ***P < 0.001.

Fig.4 IMQ induced Psoriasis model in hIL17A/hIL17F mice. 

At the study endpoint, back skin samples were harvested and hIL17F was tested by qPCR. Results indicated that Bimekizumab significantly reduced hIL17F expression level in IMQ induced Psoriasis model in hIL17A/hIL17F mice(n=6). 

Test article 1 and test article 2 are from a collaborator. Mean ± SEM. t-test, *P < 0.05.

Fig.1 IMQ induced Psoriasis model in Balb/c. (A) body weight and (B) body weight change. *P<0.05, **P<0.01, ***P<0.001 vs G2.

Fig.2 IMQ induced Psoriasis model in Balb/c. (A) ear thickness (B) skin thickness (C) cumulative score of PASI. ***P<0.001, *P<0.05 vs G2.

Fig.3 IMQ induced Psoriasis model in Balb/c. (A) erythema score, (B) skin thickness score and (C) scabby score. ***P<0.001, **P<0.01, *P<0.05 vs G2.

Fig.4 IMQ induced Psoriasis model in Balb/c. (A) spleen weight, (B) spleen index, (C) spleen image and (D) dorsal image on day3. ***P<0.001 vs G2.

Fig.5 IMQ induced Psoriasis model in Balb/c. (A) serum TNF-α, (B) serum IL-23 and (C) serum IL-17A. ***P<0.001,  *P<0.05 vs G2.

Fig.6 IMQ induced Psoriasis model in Balb/c. (A) Tnf-α (B) Il-23 (C) Il-17 mRNA expression of skin. (n=5). ***P<0.001, **P<0.01 vs G2.

Fig.7 IMQ induced Psoriasis model in Balb/c. (A) Pathological Score (B) Epidermis thickness (C) typical pathology image. ****P<0.001, **P<0.01 vs G2.

Fig.1 IMQ induced Psoriasis model based on hIL23A mice.

• Rat IL-23因子诱导的SD大鼠银屑病模型

  

Fig.1 rIL23-induced Psoriasis model in SD Rat. (A) Body weight. (B) Body weight change.

Fig.2 rIL23-induced Psoriasis model in SD Rat. (A) Ear thickness. (B) Ear thickness change. (C) PASI score.

Fig.3 Representative photo of rIL23-induced Psoriasis model in SD Rat. 

Fig.4 rIL23-induced Psoriasis model in SD Rat. (A) Representative photo of H&E staining. (B) Baker score. 

• Human IL-23因子诱导的SD大鼠银屑病模型

Fig.1 hIL23-induced Psoriasis model in SD Rat. (A) Body weight. (B) Body weight change.

Fig.2 hIL23-induced Psoriasis model in SD Rat. (A) Ear thickness. (B) Ear thickness change. (C) PASI score.

Fig.3 Representative photo of hIL23-induced Psoriasis model in SD Rat.

Fig.4 hIL23-induced Psoriasis model in SD Rat. (A) Representative photo of H&E staining. (B) Baker score.